Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 16/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101584 | 0.84 | NTRK1 (0.40) | NTRK1MAT2APRMT5CYP1A2MAPK8 | |
| SCHEMBL5101580 | 0.80 | CYP1A2 (0.45) | NTRK1MAT2APRMT5CYP1A2HTR6 | |
| SCHEMBL6355198 | 0.75 | TACR1 (0.39) | NTRK1MAT2APRMT5CYP1A2MAPK8 | |
| SCHEMBL5101582 | 0.75 | MAT2A (0.39) | NTRK1MAT2APRMT5MAPK8MAPK9 | |
| SCHEMBL5101425 | 0.74 | KMT2A (0.36) | NTRK1HTR6 | |
| SCHEMBL5089912 | 0.73 | NTRK1 (0.38) | NTRK1MAT2APRMT5HTR6 | |
| SCHEMBL5089907 | 0.72 | HTR6 (0.44) | NTRK1MAT2ACYP1A2HTR6 | |
| SCHEMBL28888717 | 0.72 | MAT2A (0.41) | NTRK1MAT2ACYP1A2CYP3A4 | |
| SCHEMBL5095637 | 0.65 | HTR6 (0.57) | HTR6 | |
| SCHEMBL28390633 | 0.65 | RAB9A (0.41) | NTRK1CYP1A2MAPK8HTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317035-B2 | Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-01-08 | — | — | US | disclosed |
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | TPH1, HTR1A, HTR5A | NTRK1 45/4885MAT2A 845/4885PRMT5 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.